查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1533956

全球定序试剂市场

Sequencing Reagents
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 250 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

预计2030年全球定序试剂市场将达128亿美元

2023年全球定序试剂市场预计为63亿美元，预计到2030年将达到128亿美元，2023年至2030年复合年增长率为10.8%。下一代定序技术是本报告分析的细分市场之一，预计复合年增长率为 11.3%，到分析期结束时将达到 84 亿美元。分析期间内，第三代定序技术领域的复合年增长率预计为 10.0%。

美国市场预计17亿美元，中国预计复合年增长率14.7%

预计2023年美国定序试剂市场规模将达17亿美元。中国作为世界第二大经济体，预计2030年市场规模将达28亿美元，2023-2030年分析期间复合年增长率为14.7%。其他值得注意的区域市场包括日本和加拿大，在分析期间预计复合年增长率分别为 8.0% 和 9.3%。在欧洲，德国的复合年增长率预计为 8.5%。

全球定序试剂市场－主要趋势与驱动因素总结

定序试剂是基因组学和分子生物学领域的关键组成部分，可准确有效地破解 DNA 和 RNA 序列。这些试剂包括酵素、核苷酸、引子和缓衝液等多种物质，每种物质在序列测定序过程中都扮演特定的角色。例如，DNA聚合酵素等酶可促进新 DNA 链的合成，而核苷酸是掺入这些链的建构模组。引子提供 DNA 合成的起点，缓衝液维持酵素反应的最佳 pH 和离子条件。桑格定序是最早开发的方法之一，它使用双脱氧核苷酸三磷酸 (ddNTP) 来阻止特定碱基处的 DNA 链延伸，从而确定 DNA 序列。新一代定序 (NGS) 技术在许多应用中取代了桑格定序，并利用标记核苷酸和聚合酵素的组合来快速、低成本地产生大量序列资料。定序的准确性、灵敏度和效率高度依赖这些试剂的品质和成分，这使得它们对于从基础研究到诊断再到临床实践的广泛应用至关重要。

技术进步对定序试剂的开发和使用产生了重大影响。降低错误率的高保真聚合酵素和增强讯号检测的改进萤光染料等创新显着提高了定序技术的准确性和通量。可以同时处理多个样本的高通量定序平台进一步推动了对标准化、可靠和高品质试剂的需求。产业公司不断致力于开发具有更高效率、更低错误率以及与各种定序平台更好相容性的试剂。例如，引入与单分子即时（SMRT）和奈米孔定序相容的试剂为研究复杂基因组和表观基因开闢了新的可能性。此外，人工智慧（AI）和机器学习（ML）在定序工作流程中的集成为开发可以即时适应和优化测序过程的更智慧试剂铺平了道路。诸如此类的进步使研究人员能够突破基因组学的极限，从而带来新的发现和应用。

测序试剂市场的成长受到多种因素的推动。首先，基因组学在个人化医疗、疾病诊断和治疗中的日益增长的应用正在推动对高品质定序试剂的需求。个人化医疗根据每位患者的独特特征量身定制治疗方案，并在很大程度上依赖基因组资讯来确定最佳治疗策略。在人类基因组计划和最近的 100,000 基因组计划等大规模倡议的推动下，基因组研究的激增继续对这些试剂产生巨大的需求。定序技术的进步，例如更有效率的 NGS 平台的开发，也透过使定序变得更容易获得和更便宜来推动市场成长。遗传疾病和癌症的盛行率不断增加，增加了定序在临床环境中的使用，进一步推动了市场的发展。此外，定序仪在农业和环境研究中的使用不断增加是推动市场扩张的另一个因素。製药公司越来越多地使用定序仪来识别新药物标靶并开发精准治疗方法。随着这些趋势的不断发展，在技术进步和各个领域广泛应用的推动下，定序试剂市场将持续成长和创新。

受访企业范例（共86家）

  • Agilent Technologies, Inc.
  • BGI Group
  • F. Hoffmann-La Roche AG
  • Illumina, Inc.
  • Integrated DNA Technologies, Inc.
  • Isogen Lifescience BV
  • LGC Limited
  • Meridian Bioscience, Inc.
  • MGI Tech Co., Ltd.
  • Pacific Biosciences of California, Inc.
  • Promega Corporation
  • QIAGEN GmbH
  • Standard BioTools, Inc.
  • Takara Bio, Inc.
  • Thermo Fisher Scientific, Inc.;

目录

第一章调查方法

第 2 章执行摘要

  • 市场概况
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 西班牙
  • 俄罗斯
  • 其他欧洲国家
  • 亚太地区
  • 澳洲
  • 印度
  • 韩国
  • 其他亚太地区
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中东
  • 伊朗
  • 以色列
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 其他中东地区
  • 非洲

第四章 比赛

简介目录
Product Code: MCP26670

Global Sequencing Reagents Market to Reach US$12.8 Billion by 2030

The global market for Sequencing Reagents estimated at US$6.3 Billion in the year 2023, is expected to reach US$12.8 Billion by 2030, growing at a CAGR of 10.8% over the analysis period 2023-2030. Next Generation Sequencing Technology, one of the segments analyzed in the report, is expected to record a 11.3% CAGR and reach US$8.4 Billion by the end of the analysis period. Growth in the Third Generation Sequencing Technology segment is estimated at 10.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.7 Billion While China is Forecast to Grow at 14.7% CAGR

The Sequencing Reagents market in the U.S. is estimated at US$1.7 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$2.8 Billion by the year 2030 trailing a CAGR of 14.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.0% and 9.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.5% CAGR.

Global Sequencing Reagents Market - Key Trends and Drivers Summarized

Sequencing reagents are crucial components in the field of genomics and molecular biology, enabling the accurate and efficient decoding of DNA and RNA sequences. These reagents include a diverse array of substances such as enzymes, nucleotides, primers, and buffers, each playing a specific role in the sequencing process. For example, enzymes like DNA polymerases facilitate the synthesis of new DNA strands, while nucleotides are the building blocks that get incorporated into these strands. Primers provide the starting point for DNA synthesis, and buffers maintain the optimal pH and ionic conditions necessary for enzymatic reactions. In Sanger sequencing, one of the earliest methods developed, dideoxynucleotide triphosphates (ddNTPs) are used to terminate DNA strand elongation at specific bases, allowing for the determination of the DNA sequence. Next-generation sequencing (NGS) technologies, which have largely supplanted Sanger sequencing for many applications, utilize a combination of labeled nucleotides and polymerases to generate vast amounts of sequence data quickly and at a lower cost. The accuracy, sensitivity, and efficiency of sequencing heavily depend on the quality and composition of these reagents, making them indispensable in a wide range of applications, from basic research to diagnostics and clinical use.

Technological advancements have significantly impacted the development and use of sequencing reagents. Innovations such as high-fidelity polymerases, which have reduced error rates, and improved fluorescent dyes, which enhance signal detection, have greatly increased the accuracy and throughput of sequencing technologies. High-throughput sequencing platforms, which can process multiple samples simultaneously, have further driven the demand for standardized, reliable, and high-quality reagents. Companies in the industry are continuously striving to develop reagents that offer higher efficiency, lower error rates, and greater compatibility with various sequencing platforms. For instance, the introduction of reagents compatible with single-molecule real-time (SMRT) sequencing and nanopore sequencing has opened new possibilities for studying complex genomes and epigenomes. Furthermore, the integration of artificial intelligence (AI) and machine learning (ML) in sequencing workflows is paving the way for the development of smarter reagents that can adapt and optimize sequencing processes in real-time. These advancements are enabling researchers to push the boundaries of what is possible in genomics, leading to new discoveries and applications.

The growth in the sequencing reagents market is driven by several factors. Firstly, the expanding applications of genomics in personalized medicine, disease diagnosis, and treatment are propelling the demand for high-quality sequencing reagents. Personalized medicine, which tailors medical treatment to the individual characteristics of each patient, relies heavily on genomic information to identify the best therapeutic strategies. The surge in genomic research, fueled by large-scale initiatives like the Human Genome Project and the more recent 100,000 Genomes Project, continues to generate significant demand for these reagents. Advances in sequencing technologies, such as the development of more efficient NGS platforms, are also driving market growth by making sequencing more accessible and affordable. The increasing prevalence of genetic disorders and cancer has led to a rise in the use of sequencing in clinical settings, further boosting the market. Additionally, the growing use of sequencing in agricultural and environmental research is another factor contributing to market expansion. Pharmaceutical companies are increasingly using sequencing to identify new drug targets and to develop precision therapies. As these trends continue to evolve, the sequencing reagents market is poised for sustained growth and innovation, driven by technological advancements and expanding applications across various fields.

Select Competitors (Total 86 Featured) -

  • Agilent Technologies, Inc.
  • BGI Group
  • F. Hoffmann-La Roche AG
  • Illumina, Inc.
  • Integrated DNA Technologies, Inc.
  • Isogen Lifescience B.V.
  • LGC Limited
  • Meridian Bioscience, Inc.
  • MGI Tech Co., Ltd.
  • Pacific Biosciences of California, Inc.
  • Promega Corporation
  • QIAGEN GmbH
  • Standard BioTools, Inc.
  • Takara Bio, Inc.
  • Thermo Fisher Scientific, Inc.;

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Sequencing Reagents - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Surge in Genomic Research Initiatives Drives Demand for High-Quality Reagents
    • Development of Enhanced Fluorescent Dyes Strengthens Business Case for Sequencing Reagents
    • Increasing Applications of Genomics in Personalized Medicine Expands Addressable Market Opportunity
    • Technological Innovations in Next-Generation Sequencing Platforms Spur Market Expansion
    • Growing Prevalence of Genetic Disorders and Cancer Accelerates Demand for Clinical Sequencing
    • Adoption of Single-Molecule Real-Time (SMRT) and Nanopore Sequencing Technologies Throws Spotlight on Innovative Reagents
    • Integration of AI and Machine Learning in Sequencing Workflows Generates New Opportunities for Smarter Reagents
    • Expansion of Agricultural and Environmental Sequencing Applications Propels Market Growth
    • Increased Investment in Biotechnology and Pharmaceutical Research Strengthens Market Dynamics
    • Continuous Development of Automated Sequencing Platforms Expands Market Reach
    • Emergence of New Sequencing Applications in Microbiome and Epigenetics Research Generates Demand
    • Expansion of Genomic Data Analysis Tools and Software Strengthens Business Case for Reagent Use
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Sequencing Reagents Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Sequencing Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Sequencing Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Sequencing Reagents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Next Generation Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Next Generation Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Next Generation Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Third Generation Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Third Generation Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Third Generation Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Sanger Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Sanger Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Sanger Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Hospitals & Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Pharma & Biotech Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Academic Research End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Academic Research End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Academic Research End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Clinical Research End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Clinical Research End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Clinical Research End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Reproductive Health Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Reproductive Health Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: World 16-Year Perspective for Reproductive Health Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: World 16-Year Perspective for Oncology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Clinical Investigation Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Clinical Investigation Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: World 16-Year Perspective for Clinical Investigation Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Sequencing Reagents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 41: USA Recent Past, Current & Future Analysis for Sequencing Reagents by Technology Type - Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Sequencing Reagents by Technology Type - Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Sequencing Reagents by Technology Type - Percentage Breakdown of Value Sales for Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing for the Years 2014, 2024 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Sequencing Reagents by End-Use - Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Sequencing Reagents by End-Use - Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: USA 16-Year Perspective for Sequencing Reagents by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use for the Years 2014, 2024 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Sequencing Reagents by Application - Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Sequencing Reagents by Application - Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: USA 16-Year Perspective for Sequencing Reagents by Application - Percentage Breakdown of Value Sales for Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Sequencing Reagents by Technology Type - Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Sequencing Reagents by Technology Type - Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Sequencing Reagents by Technology Type - Percentage Breakdown of Value Sales for Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing for the Years 2014, 2024 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Sequencing Reagents by End-Use - Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Sequencing Reagents by End-Use - Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Canada 16-Year Perspective for Sequencing Reagents by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use for the Years 2014, 2024 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Sequencing Reagents by Application - Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Sequencing Reagents by Application - Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Canada 16-Year Perspective for Sequencing Reagents by Application - Percentage Breakdown of Value Sales for Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications for the Years 2014, 2024 & 2030
  • JAPAN
    • Sequencing Reagents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Sequencing Reagents by Technology Type - Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Sequencing Reagents by Technology Type - Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Japan 16-Year Perspective for Sequencing Reagents by Technology Type - Percentage Breakdown of Value Sales for Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing for the Years 2014, 2024 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Sequencing Reagents by End-Use - Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Sequencing Reagents by End-Use - Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Japan 16-Year Perspective for Sequencing Reagents by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use for the Years 2014, 2024 & 2030
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Sequencing Reagents by Application - Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Sequencing Reagents by Application - Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Japan 16-Year Perspective for Sequencing Reagents by Application - Percentage Breakdown of Value Sales for Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications for the Years 2014, 2024 & 2030
  • CHINA
    • Sequencing Reagents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 68: China Recent Past, Current & Future Analysis for Sequencing Reagents by Technology Type - Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Sequencing Reagents by Technology Type - Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: China 16-Year Perspective for Sequencing Reagents by Technology Type - Percentage Breakdown of Value Sales for Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing for the Years 2014, 2024 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Sequencing Reagents by End-Use - Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Sequencing Reagents by End-Use - Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: China 16-Year Perspective for Sequencing Reagents by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use for the Years 2014, 2024 & 2030
    • TABLE 74: China Recent Past, Current & Future Analysis for Sequencing Reagents by Application - Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Sequencing Reagents by Application - Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: China 16-Year Perspective for Sequencing Reagents by Application - Percentage Breakdown of Value Sales for Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications for the Years 2014, 2024 & 2030
  • EUROPE
    • Sequencing Reagents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Sequencing Reagents by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Sequencing Reagents by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Sequencing Reagents by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Sequencing Reagents by Technology Type - Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Sequencing Reagents by Technology Type - Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Sequencing Reagents by Technology Type - Percentage Breakdown of Value Sales for Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing for the Years 2014, 2024 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Sequencing Reagents by End-Use - Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Sequencing Reagents by End-Use - Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Europe 16-Year Perspective for Sequencing Reagents by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use for the Years 2014, 2024 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Sequencing Reagents by Application - Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Sequencing Reagents by Application - Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Europe 16-Year Perspective for Sequencing Reagents by Application - Percentage Breakdown of Value Sales for Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications for the Years 2014, 2024 & 2030
  • FRANCE
    • Sequencing Reagents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 89: France Recent Past, Current & Future Analysis for Sequencing Reagents by Technology Type - Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Sequencing Reagents by Technology Type - Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: France 16-Year Perspective for Sequencing Reagents by Technology Type - Percentage Breakdown of Value Sales for Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing for the Years 2014, 2024 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Sequencing Reagents by End-Use - Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Sequencing Reagents by End-Use - Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: France 16-Year Perspective for Sequencing Reagents by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use for the Years 2014, 2024 & 2030
    • TABLE 95: France Recent Past, Current & Future Analysis for Sequencing Reagents by Application - Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: France Historic Review for Sequencing Reagents by Application - Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: France 16-Year Perspective for Sequencing Reagents by Application - Percentage Breakdown of Value Sales for Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications for the Years 2014, 2024 & 2030
  • GERMANY
    • Sequencing Reagents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Sequencing Reagents by Technology Type - Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Sequencing Reagents by Technology Type - Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Germany 16-Year Perspective for Sequencing Reagents by Technology Type - Percentage Breakdown of Value Sales for Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing for the Years 2014, 2024 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Sequencing Reagents by End-Use - Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Sequencing Reagents by End-Use - Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Germany 16-Year Perspective for Sequencing Reagents by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use for the Years 2014, 2024 & 2030
    • TABLE 104: Germany Recent Past, Current & Future Analysis for Sequencing Reagents by Application - Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Germany Historic Review for Sequencing Reagents by Application - Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Germany 16-Year Perspective for Sequencing Reagents by Application - Percentage Breakdown of Value Sales for Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Sequencing Reagents by Technology Type - Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Sequencing Reagents by Technology Type - Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Italy 16-Year Perspective for Sequencing Reagents by Technology Type - Percentage Breakdown of Value Sales for Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing for the Years 2014, 2024 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Sequencing Reagents by End-Use - Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Sequencing Reagents by End-Use - Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Italy 16-Year Perspective for Sequencing Reagents by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use for the Years 2014, 2024 & 2030
    • TABLE 113: Italy Recent Past, Current & Future Analysis for Sequencing Reagents by Application - Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Italy Historic Review for Sequencing Reagents by Application - Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Italy 16-Year Perspective for Sequencing Reagents by Application - Percentage Breakdown of Value Sales for Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Sequencing Reagents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 116: UK Recent Past, Current & Future Analysis for Sequencing Reagents by Technology Type - Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Sequencing Reagents by Technology Type - Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: UK 16-Year Perspective for Sequencing Reagents by Technology Type - Percentage Breakdown of Value Sales for Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing for the Years 2014, 2024 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Sequencing Reagents by End-Use - Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Sequencing Reagents by End-Use - Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: UK 16-Year Perspective for Sequencing Reagents by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use for the Years 2014, 2024 & 2030
    • TABLE 122: UK Recent Past, Current & Future Analysis for Sequencing Reagents by Application - Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: UK Historic Review for Sequencing Reagents by Application - Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: UK 16-Year Perspective for Sequencing Reagents by Application - Percentage Breakdown of Value Sales for Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Sequencing Reagents by Technology Type - Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Sequencing Reagents by Technology Type - Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: Spain 16-Year Perspective for Sequencing Reagents by Technology Type - Percentage Breakdown of Value Sales for Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing for the Years 2014, 2024 & 2030
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Sequencing Reagents by End-Use - Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Sequencing Reagents by End-Use - Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Spain 16-Year Perspective for Sequencing Reagents by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use for the Years 2014, 2024 & 2030
    • TABLE 131: Spain Recent Past, Current & Future Analysis for Sequencing Reagents by Application - Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Spain Historic Review for Sequencing Reagents by Application - Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Spain 16-Year Perspective for Sequencing Reagents by Application - Percentage Breakdown of Value Sales for Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Sequencing Reagents by Technology Type - Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Sequencing Reagents by Technology Type - Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Russia 16-Year Perspective for Sequencing Reagents by Technology Type - Percentage Breakdown of Value Sales for Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing for the Years 2014, 2024 & 2030
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Sequencing Reagents by End-Use - Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Sequencing Reagents by End-Use - Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Russia 16-Year Perspective for Sequencing Reagents by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use for the Years 2014, 2024 & 2030
    • TABLE 140: Russia Recent Past, Current & Future Analysis for Sequencing Reagents by Application - Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Russia Historic Review for Sequencing Reagents by Application - Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Russia 16-Year Perspective for Sequencing Reagents by Application - Percentage Breakdown of Value Sales for Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Sequencing Reagents by Technology Type - Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Sequencing Reagents by Technology Type - Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Rest of Europe 16-Year Perspective for Sequencing Reagents by Technology Type - Percentage Breakdown of Value Sales for Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing for the Years 2014, 2024 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Sequencing Reagents by End-Use - Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Sequencing Reagents by End-Use - Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Rest of Europe 16-Year Perspective for Sequencing Reagents by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use for the Years 2014, 2024 & 2030
    • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Sequencing Reagents by Application - Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Rest of Europe Historic Review for Sequencing Reagents by Application - Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Rest of Europe 16-Year Perspective for Sequencing Reagents by Application - Percentage Breakdown of Value Sales for Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Sequencing Reagents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Sequencing Reagents by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Sequencing Reagents by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Sequencing Reagents by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Sequencing Reagents by Technology Type - Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Sequencing Reagents by Technology Type - Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Asia-Pacific 16-Year Perspective for Sequencing Reagents by Technology Type - Percentage Breakdown of Value Sales for Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing for the Years 2014, 2024 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Sequencing Reagents by End-Use - Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Sequencing Reagents by End-Use - Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Asia-Pacific 16-Year Perspective for Sequencing Reagents by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use for the Years 2014, 2024 & 2030
    • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Sequencing Reagents by Application - Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Asia-Pacific Historic Review for Sequencing Reagents by Application - Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Asia-Pacific 16-Year Perspective for Sequencing Reagents by Application - Percentage Breakdown of Value Sales for Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Sequencing Reagents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Sequencing Reagents by Technology Type - Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Sequencing Reagents by Technology Type - Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Australia 16-Year Perspective for Sequencing Reagents by Technology Type - Percentage Breakdown of Value Sales for Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing for the Years 2014, 2024 & 2030
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Sequencing Reagents by End-Use - Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Sequencing Reagents by End-Use - Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Australia 16-Year Perspective for Sequencing Reagents by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use for the Years 2014, 2024 & 2030
    • TABLE 170: Australia Recent Past, Current & Future Analysis for Sequencing Reagents by Application - Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Australia Historic Review for Sequencing Reagents by Application - Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Australia 16-Year Perspective for Sequencing Reagents by Application - Percentage Breakdown of Value Sales for Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications for the Years 2014, 2024 & 2030
  • INDIA
    • Sequencing Reagents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 173: India Recent Past, Current & Future Analysis for Sequencing Reagents by Technology Type - Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Sequencing Reagents by Technology Type - Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: India 16-Year Perspective for Sequencing Reagents by Technology Type - Percentage Breakdown of Value Sales for Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing for the Years 2014, 2024 & 2030
    • TABLE 176: India Recent Past, Current & Future Analysis for Sequencing Reagents by End-Use - Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Sequencing Reagents by End-Use - Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: India 16-Year Perspective for Sequencing Reagents by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use for the Years 2014, 2024 & 2030
    • TABLE 179: India Recent Past, Current & Future Analysis for Sequencing Reagents by Application - Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: India Historic Review for Sequencing Reagents by Application - Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: India 16-Year Perspective for Sequencing Reagents by Application - Percentage Breakdown of Value Sales for Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Sequencing Reagents by Technology Type - Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Sequencing Reagents by Technology Type - Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: South Korea 16-Year Perspective for Sequencing Reagents by Technology Type - Percentage Breakdown of Value Sales for Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing for the Years 2014, 2024 & 2030
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Sequencing Reagents by End-Use - Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Sequencing Reagents by End-Use - Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: South Korea 16-Year Perspective for Sequencing Reagents by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use for the Years 2014, 2024 & 2030
    • TABLE 188: South Korea Recent Past, Current & Future Analysis for Sequencing Reagents by Application - Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: South Korea Historic Review for Sequencing Reagents by Application - Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: South Korea 16-Year Perspective for Sequencing Reagents by Application - Percentage Breakdown of Value Sales for Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Sequencing Reagents by Technology Type - Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Sequencing Reagents by Technology Type - Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Sequencing Reagents by Technology Type - Percentage Breakdown of Value Sales for Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing for the Years 2014, 2024 & 2030
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Sequencing Reagents by End-Use - Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Sequencing Reagents by End-Use - Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Sequencing Reagents by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use for the Years 2014, 2024 & 2030
    • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Sequencing Reagents by Application - Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Rest of Asia-Pacific Historic Review for Sequencing Reagents by Application - Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Rest of Asia-Pacific 16-Year Perspective for Sequencing Reagents by Application - Percentage Breakdown of Value Sales for Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Sequencing Reagents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Sequencing Reagents by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Sequencing Reagents by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Sequencing Reagents by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Sequencing Reagents by Technology Type - Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Sequencing Reagents by Technology Type - Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Latin America 16-Year Perspective for Sequencing Reagents by Technology Type - Percentage Breakdown of Value Sales for Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing for the Years 2014, 2024 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Sequencing Reagents by End-Use - Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Sequencing Reagents by End-Use - Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Latin America 16-Year Perspective for Sequencing Reagents by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use for the Years 2014, 2024 & 2030
    • TABLE 209: Latin America Recent Past, Current & Future Analysis for Sequencing Reagents by Application - Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Latin America Historic Review for Sequencing Reagents by Application - Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: Latin America 16-Year Perspective for Sequencing Reagents by Application - Percentage Breakdown of Value Sales for Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Sequencing Reagents by Technology Type - Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Sequencing Reagents by Technology Type - Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 214: Argentina 16-Year Perspective for Sequencing Reagents by Technology Type - Percentage Breakdown of Value Sales for Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing for the Years 2014, 2024 & 2030
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Sequencing Reagents by End-Use - Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Sequencing Reagents by End-Use - Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 217: Argentina 16-Year Perspective for Sequencing Reagents by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use for the Years 2014, 2024 & 2030
    • TABLE 218: Argentina Recent Past, Current & Future Analysis for Sequencing Reagents by Application - Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 219: Argentina Historic Review for Sequencing Reagents by Application - Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 220: Argentina 16-Year Perspective for Sequencing Reagents by Application - Percentage Breakdown of Value Sales for Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Sequencing Reagents by Technology Type - Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Sequencing Reagents by Technology Type - Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 223: Brazil 16-Year Perspective for Sequencing Reagents by Technology Type - Percentage Breakdown of Value Sales for Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing for the Years 2014, 2024 & 2030
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Sequencing Reagents by End-Use - Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Sequencing Reagents by End-Use - Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 226: Brazil 16-Year Perspective for Sequencing Reagents by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use for the Years 2014, 2024 & 2030
    • TABLE 227: Brazil Recent Past, Current & Future Analysis for Sequencing Reagents by Application - Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 228: Brazil Historic Review for Sequencing Reagents by Application - Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 229: Brazil 16-Year Perspective for Sequencing Reagents by Application - Percentage Breakdown of Value Sales for Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Sequencing Reagents by Technology Type - Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Sequencing Reagents by Technology Type - Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 232: Mexico 16-Year Perspective for Sequencing Reagents by Technology Type - Percentage Breakdown of Value Sales for Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing for the Years 2014, 2024 & 2030
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Sequencing Reagents by End-Use - Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Sequencing Reagents by End-Use - Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 235: Mexico 16-Year Perspective for Sequencing Reagents by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use for the Years 2014, 2024 & 2030
    • TABLE 236: Mexico Recent Past, Current & Future Analysis for Sequencing Reagents by Application - Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 237: Mexico Historic Review for Sequencing Reagents by Application - Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 238: Mexico 16-Year Perspective for Sequencing Reagents by Application - Percentage Breakdown of Value Sales for Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Sequencing Reagents by Technology Type - Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Sequencing Reagents by Technology Type - Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 241: Rest of Latin America 16-Year Perspective for Sequencing Reagents by Technology Type - Percentage Breakdown of Value Sales for Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing for the Years 2014, 2024 & 2030
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Sequencing Reagents by End-Use - Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Sequencing Reagents by End-Use - Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 244: Rest of Latin America 16-Year Perspective for Sequencing Reagents by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use for the Years 2014, 2024 & 2030
    • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Sequencing Reagents by Application - Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 246: Rest of Latin America Historic Review for Sequencing Reagents by Application - Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 247: Rest of Latin America 16-Year Perspective for Sequencing Reagents by Application - Percentage Breakdown of Value Sales for Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Sequencing Reagents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Sequencing Reagents by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Sequencing Reagents by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Sequencing Reagents by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Sequencing Reagents by Technology Type - Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Sequencing Reagents by Technology Type - Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 253: Middle East 16-Year Perspective for Sequencing Reagents by Technology Type - Percentage Breakdown of Value Sales for Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing for the Years 2014, 2024 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Sequencing Reagents by End-Use - Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Sequencing Reagents by End-Use - Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 256: Middle East 16-Year Perspective for Sequencing Reagents by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use for the Years 2014, 2024 & 2030
    • TABLE 257: Middle East Recent Past, Current & Future Analysis for Sequencing Reagents by Application - Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 258: Middle East Historic Review for Sequencing Reagents by Application - Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 259: Middle East 16-Year Perspective for Sequencing Reagents by Application - Percentage Breakdown of Value Sales for Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Sequencing Reagents by Technology Type - Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Sequencing Reagents by Technology Type - Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 262: Iran 16-Year Perspective for Sequencing Reagents by Technology Type - Percentage Breakdown of Value Sales for Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing for the Years 2014, 2024 & 2030
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Sequencing Reagents by End-Use - Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Sequencing Reagents by End-Use - Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 265: Iran 16-Year Perspective for Sequencing Reagents by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use for the Years 2014, 2024 & 2030
    • TABLE 266: Iran Recent Past, Current & Future Analysis for Sequencing Reagents by Application - Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 267: Iran Historic Review for Sequencing Reagents by Application - Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 268: Iran 16-Year Perspective for Sequencing Reagents by Application - Percentage Breakdown of Value Sales for Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Sequencing Reagents by Technology Type - Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Sequencing Reagents by Technology Type - Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 271: Israel 16-Year Perspective for Sequencing Reagents by Technology Type - Percentage Breakdown of Value Sales for Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing for the Years 2014, 2024 & 2030
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Sequencing Reagents by End-Use - Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Sequencing Reagents by End-Use - Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 274: Israel 16-Year Perspective for Sequencing Reagents by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use for the Years 2014, 2024 & 2030
    • TABLE 275: Israel Recent Past, Current & Future Analysis for Sequencing Reagents by Application - Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 276: Israel Historic Review for Sequencing Reagents by Application - Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 277: Israel 16-Year Perspective for Sequencing Reagents by Application - Percentage Breakdown of Value Sales for Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Sequencing Reagents by Technology Type - Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Sequencing Reagents by Technology Type - Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 280: Saudi Arabia 16-Year Perspective for Sequencing Reagents by Technology Type - Percentage Breakdown of Value Sales for Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing for the Years 2014, 2024 & 2030
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Sequencing Reagents by End-Use - Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Sequencing Reagents by End-Use - Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 283: Saudi Arabia 16-Year Perspective for Sequencing Reagents by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use for the Years 2014, 2024 & 2030
    • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Sequencing Reagents by Application - Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 285: Saudi Arabia Historic Review for Sequencing Reagents by Application - Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 286: Saudi Arabia 16-Year Perspective for Sequencing Reagents by Application - Percentage Breakdown of Value Sales for Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Sequencing Reagents by Technology Type - Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Sequencing Reagents by Technology Type - Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 289: UAE 16-Year Perspective for Sequencing Reagents by Technology Type - Percentage Breakdown of Value Sales for Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing for the Years 2014, 2024 & 2030
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Sequencing Reagents by End-Use - Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Sequencing Reagents by End-Use - Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 292: UAE 16-Year Perspective for Sequencing Reagents by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use for the Years 2014, 2024 & 2030
    • TABLE 293: UAE Recent Past, Current & Future Analysis for Sequencing Reagents by Application - Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 294: UAE Historic Review for Sequencing Reagents by Application - Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 295: UAE 16-Year Perspective for Sequencing Reagents by Application - Percentage Breakdown of Value Sales for Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Sequencing Reagents by Technology Type - Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Sequencing Reagents by Technology Type - Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 298: Rest of Middle East 16-Year Perspective for Sequencing Reagents by Technology Type - Percentage Breakdown of Value Sales for Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing for the Years 2014, 2024 & 2030
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Sequencing Reagents by End-Use - Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Sequencing Reagents by End-Use - Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 301: Rest of Middle East 16-Year Perspective for Sequencing Reagents by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use for the Years 2014, 2024 & 2030
    • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Sequencing Reagents by Application - Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 303: Rest of Middle East Historic Review for Sequencing Reagents by Application - Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 304: Rest of Middle East 16-Year Perspective for Sequencing Reagents by Application - Percentage Breakdown of Value Sales for Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications for the Years 2014, 2024 & 2030
  • AFRICA
    • Sequencing Reagents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Sequencing Reagents by Technology Type - Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Sequencing Reagents by Technology Type - Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 307: Africa 16-Year Perspective for Sequencing Reagents by Technology Type - Percentage Breakdown of Value Sales for Next Generation Sequencing, Third Generation Sequencing and Sanger Sequencing for the Years 2014, 2024 & 2030
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Sequencing Reagents by End-Use - Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Sequencing Reagents by End-Use - Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 310: Africa 16-Year Perspective for Sequencing Reagents by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Pharma & Biotech Companies End-Use, Other End-Uses, Academic Research End-Use and Clinical Research End-Use for the Years 2014, 2024 & 2030
    • TABLE 311: Africa Recent Past, Current & Future Analysis for Sequencing Reagents by Application - Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 312: Africa Historic Review for Sequencing Reagents by Application - Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 313: Africa 16-Year Perspective for Sequencing Reagents by Application - Percentage Breakdown of Value Sales for Reproductive Health Application, Oncology Application, Clinical Investigation Application and Other Applications for the Years 2014, 2024 & 2030

IV. COMPETITION